This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF).
Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants with other malignant tumors within 3 years before the first dose of study treatment.
Active or untreated central nervous system (CNS) metastasis.
Current uncontrolled concomitant diseases
Clinically severe lung damage due to complications of lung disorder